Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT00234052
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
    5 mg/kg administered intravenously over 90 minutes on day 1 of each cycle (cycle = 3 weeks)
  • carboplatin — DRUG
    Administered intravenously at a dose of AUC=6 over 30 minutes on day 1 of each cycle (1 cycle = 3 weeks)
  • pemetrexed — DRUG
    Administered intravenously at a dose of 500 mg/m2 over 10 minutes on day 1 of each cycle (1 cycle = 3 weeks)

Study Details

RATIONALE: Drugs used in chemotherapy, such as carboplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving carboplatin and pemetrexed disodium together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving carboplatin and pemetrexed disodium together with bevacizumab works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer.

Key Dates

First listed
Oct 6, 2005
Start date
Jul 28, 2005
Status verified
Jan 2019
Primary completion
Mar 1, 2011
Completion
Nov 28, 2011

Study Design

Enrollment
51 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Arm
    Carboplatin + pemetrexed + bevacizumab

Primary Outcome Measure

Median Progression Free Survival [ Time Frame: Approximately every 3 weeks until disease progression or death. Median follow up of 13 months (range 0.8 to 34.4 months) ]

Locations (5)

FacilityCityStateZIPSite coordinators
Robert H. Lurie Comprehensive Cancer Center at Northwestern UniversityChicagoIllinois60611-3013-
Rush Cancer Institute at Rush University Medical CenterChicagoIllinois60612-
Evanston Northwestern Healthcare - Evanston HospitalEvanstonIllinois60201-1781-
Ingalls Cancer Care Center at Ingalls Memorial HospitalHarveyIllinois60426-
Advocate Lutheran General Cancer Care CenterPark RidgeIllinois60068-1174-

Find similar trials in Chicago, IL

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Robert H. Lurie Comprehensive Cancer Center at Northwestern University· Chicago, ILRush Cancer Institute at Rush University Medical Center· Chicago, ILEvanston Northwestern Healthcare - Evanston Hospital· Evanston, ILIngalls Cancer Care Center at Ingalls Memorial Hospital· Harvey, ILAdvocate Lutheran General Cancer Care Center· Park Ridge, IL

Related Studies